KR20230107566A - 세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물 - Google Patents

세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물 Download PDF

Info

Publication number
KR20230107566A
KR20230107566A KR1020237015543A KR20237015543A KR20230107566A KR 20230107566 A KR20230107566 A KR 20230107566A KR 1020237015543 A KR1020237015543 A KR 1020237015543A KR 20237015543 A KR20237015543 A KR 20237015543A KR 20230107566 A KR20230107566 A KR 20230107566A
Authority
KR
South Korea
Prior art keywords
methyl
dimethylamino
ethoxy
phenyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015543A
Other languages
English (en)
Korean (ko)
Inventor
라리아 줄리오 카스트로-팔로미노
고메즈 후안 알베르토 카마초
리수에뇨 루스 무뇨스
리즈 클레멘트-디망지
Original Assignee
레우코스 바이오테크 에스. 엘.
푼다시오 인스티뚜트 데 레세르카 꼰뜨라 라 레우세미아 요셉 까를레라스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레우코스 바이오테크 에스. 엘., 푼다시오 인스티뚜트 데 레세르카 꼰뜨라 라 레우세미아 요셉 까를레라스 filed Critical 레우코스 바이오테크 에스. 엘.
Publication of KR20230107566A publication Critical patent/KR20230107566A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237015543A 2020-10-08 2021-10-07 세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물 Pending KR20230107566A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382888.4 2020-10-08
EP20382888 2020-10-08
PCT/EP2021/077660 WO2022074103A1 (en) 2020-10-08 2021-10-07 Potent and selctive compounds as serotonin 1b receptor modulators

Publications (1)

Publication Number Publication Date
KR20230107566A true KR20230107566A (ko) 2023-07-17

Family

ID=73030029

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015543A Pending KR20230107566A (ko) 2020-10-08 2021-10-07 세로토닌 1b 수용체 조절제로서 효력있고 선택적인 화합물

Country Status (21)

Country Link
US (1) US12540133B2 (enExample)
EP (2) EP4445901A3 (enExample)
JP (1) JP7687636B2 (enExample)
KR (1) KR20230107566A (enExample)
CN (1) CN116635390B (enExample)
AU (1) AU2021356114A1 (enExample)
CA (1) CA3194700A1 (enExample)
CL (1) CL2023001021A1 (enExample)
DK (1) DK4225753T3 (enExample)
ES (1) ES2985416T3 (enExample)
FI (1) FI4225753T3 (enExample)
HR (1) HRP20241184T1 (enExample)
HU (1) HUE068199T2 (enExample)
IL (1) IL301806B1 (enExample)
LT (1) LT4225753T (enExample)
MX (1) MX2023004116A (enExample)
PL (1) PL4225753T3 (enExample)
PT (1) PT4225753T (enExample)
RS (1) RS65956B1 (enExample)
SI (1) SI4225753T1 (enExample)
WO (1) WO2022074103A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123701A1 (es) 2020-10-08 2023-01-04 Merck Sharp & Dohme Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
EP4382519A4 (en) * 2021-08-27 2024-12-04 Adlai Nortye Biopharma Co., Ltd. CYCLIN K DEGRADING AGENT
AU2024302643A1 (en) 2023-06-16 2026-01-22 Leukos Biotech Sl 5-htr1b modulator for use in the treatment of solid tumours

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW240217B (enExample) * 1992-12-30 1995-02-11 Glaxo Group Ltd
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
ZA985542B (en) * 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
EP1098892A1 (en) 1998-07-20 2001-05-16 MERCK PATENT GmbH Biphenyl derivatives
BR0112856A (pt) 2000-07-31 2003-07-01 Smithkline Beecham Plc Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
WO2007077457A2 (en) * 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
EP3348266A1 (en) 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer

Also Published As

Publication number Publication date
HRP20241184T1 (hr) 2024-11-22
DK4225753T3 (da) 2024-08-19
WO2022074103A1 (en) 2022-04-14
JP7687636B2 (ja) 2025-06-03
MX2023004116A (es) 2023-06-13
EP4225753A1 (en) 2023-08-16
CN116635390A (zh) 2023-08-22
CN116635390B (zh) 2026-03-27
RS65956B1 (sr) 2024-10-31
CL2023001021A1 (es) 2023-11-24
US20240166639A1 (en) 2024-05-23
LT4225753T (lt) 2024-08-26
JP2023547346A (ja) 2023-11-10
IL301806B1 (en) 2026-01-01
EP4445901A2 (en) 2024-10-16
AU2021356114A1 (en) 2023-05-18
AU2021356114A9 (en) 2024-09-12
HUE068199T2 (hu) 2024-12-28
SI4225753T1 (sl) 2024-10-30
PT4225753T (pt) 2024-08-30
EP4225753B1 (en) 2024-07-31
FI4225753T3 (fi) 2024-08-29
PL4225753T3 (pl) 2024-11-18
US12540133B2 (en) 2026-02-03
EP4445901A3 (en) 2024-12-04
IL301806A (en) 2023-05-01
ES2985416T3 (es) 2024-11-05
CA3194700A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CN112552294B (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
CN113214287B (zh) Hpk1抑制剂及其使用方法
CN110573500B (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
JP2023536948A (ja) Ｅｇｆｒ阻害剤およびその製造方法と応用
CN111601790B (zh) 作为蛋白激酶抑制剂的杂芳基化合物
CN118221698A (zh) Kras g12d抑制剂
JP7687636B2 (ja) セロトニン１ｂ受容体モジュレーターとしての強力で選択的な新規化合物
CN105968115B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
KR20110016998A (ko) 키나제 억제제로서의 아자카르볼린 유도체, 그의 제조 및 그의 치료 용도
TWI891753B (zh) 醯胺類化合物及其用途
JP2021536436A (ja) キノリン誘導体から調製される新規な阻害剤
IL305046A (en) Pyridopyrimidinone derivative, the method of preparation thereof and its use
CN105712992A (zh) 作为cMet抑制剂的化合物及其制备方法和用途
JPWO2016098793A1 (ja) 環状グアニジル基を有するチアゾール誘導体
JP2024516194A (ja) Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法
CN107056754B (zh) 内嵌脲类结构的wnt通路抑制剂
HK40057478B (zh) Hpk1抑制剂及其使用方法
JP2025526321A (ja) Ｔｅａｄ阻害薬および使用方法
JP2025539873A (ja) Ｈｕｒ（ｅｌａｖｌ１）を調節するための化合物
HK40047614B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK40047614A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902